• Users Online: 72
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 3  |  Issue : 2  |  Page : 40-45

Chronic mitral regurgitation: Does atrial fibrillation impact outcome in patients managed with medical therapy only?


1 Dr. Joe Nwiloh Heart Center, St. Joseph's Hospital, Adazi Nnukwu, Anambra State, Nigeria
2 Department of Medicine, University of Nigeria Teaching Hospital, Ituku Ozalla, Enugu State, Nigeria

Correspondence Address:
Jonathan Nwiloh
Dr. Joe Nwiloh Heart Center, St. Joseph's Hospital, Adazi Nnukwu, Anambra State, Adazi Nnukwu, Anambra State
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/njct.njct_2_19

Rights and Permissions

Background: The AHA/ACC guideline recommends surgery for symptomatic chronic severe mitral regurgitation or percutaneous mitral valve repair for high surgical risk or inoperable patients. Although atrial fibrillation (AF) is a known predictor of survival after either of these interventional procedures, its impact on the outcome of patients treated only medically is less well defined. Materials and Methods: This was a retrospective review of adult patients with chronic mitral regurgitation seen at our heart center from August 2014 to December 2017. Results: There were 102 patients, with a mean age of 58.4 ± 15.8 years and 51% were males. Major comorbidities were AF (58.8%), hypertension (HTN) (53.9%), pulmonary HTN (18.6%), and diabetes mellitus (10.8%). Sixty-seven (65.7%) patients had primary and 35 (34.3%) had secondary mitral regurgitation. Eighty-eight (86.3%) patients were in New York Heart Association Class 3/4, 92 (90.2%) in AHA/ACC Stages C/D, and 70 (68.6%) had left ventricular (LV) dysfunction with ejection fraction (EF) <60. Patients were subdivided into Group 1 – 60 (58.8%) patients with AF and Group 2 – 42 (41.2%) patients without AF. AF frequency was higher with primary or degenerative mitral regurgitation (PMR) versus secondary mitral regurgitation (SMR), 75% versus 25%, P = 0.031, whereas HTN was higher in SMR versus PMR, 77.1% versus 41.8%, P = 0.001. Four patients underwent mitral valve replacement and two patients implantable cardioverter defibrillator. All patients were treated with the AHA/ACC guideline-directed medical therapy (GDMT). All-cause mortality for Groups 1 and 2 was 25% and 14.3%, respectively, odds ratio was 2.0, and 95% confidence interval was 0.705–5.677, P = 0.285. Overall, Kaplan–Meier survival at 30 months was 63%, and log-rank analysis survival was 56% and 79% for Groups 1 and 2, respectively, P = 0.345. Conclusion: In a cohort of patients with chronic mitral regurgitation treated only medically with GDMT in a low-resource country, all-cause mortality and intermediate survival were comparable between AF and non AF patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed496    
    Printed73    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal